•  
  •  
  •  
  •  

2023-12-12 04:58:14

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • BLS International again wins the Contract with the High Commission of India in Canada
  • Vikas Ecotech's Debt Reduction Program
  • REC enters into 200 million Euro Loan Agreement with German Bank KfW
  • TVS Motor Company extends INR 50 Lakhs Relief Aid to Andhra Pradesh
  • Moneyboxx Finance Ltd opens its 83rd branch office

Keywords Selected:  Lupin

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin receives approval from U.S. FDA for Varenicline Tablets
  • Lupin Launches Turqoz® Tablets USP in the United States
  • Lupin receives tentative approval from U.S. FDA for Canagliflozin Tablets
  • Lupin receives approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.07%
  • Lupin Launches World's First Fixed-dose Triple Combination Drug, Vilfuro-G® for COPD Management in India
  • Lupin receives approval from U.S. FDA for Pitavastatin Tablets
  • Lupin receives tentative approval from U.S. FDA for Dapagliflozin Tablets
  • Lupin receives approval from U.S. FDA for Ganirelix Acetate Injection
  • Lupin receives tentative approval from U.S. FDA for Selexipag for Injection
  • Lupin receives EIR from U.S. FDA for its Mandideep Unit-2 Manufacturing Facility
  • Lupin Ltd enters into BTA with Lupin Manufacturing Solutions Ltd
  • Lupin receives tentative approval from U.S. FDA for Apalutamide Tablets
  • Lupin Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution
  • Lupin receives tentative approval from U.S. FDA for Tolvaptan Tablets
  • Lupin Launches Humrahi - Unique Patient Support Program for Diabetes Management
  • Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 Manufacturing Facility
  • Lupin's Joint Airways Initiative surpasses 10,000 Patients
  • Lupin acquires Five Brands from Menarini
  • Lupin Collaborates with Mark Cuban Cost Plus Drug Company and COPD Foundation to Expand Access to Medication for COPD Patients
  • Lupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada
  • Lupin Receives Approval from U.S. FDA for Pirfenidone Capsules
  • Lupin receives approval from U.S. FDA for Pirfenidone Tablets
  • Lupin acquires brands ONDERO® and ONDERO MET® to expand Diabetes Portfolio in India
  • Lupin Launches Tiotropium Dry Powder for Inhaler for the Treatment of COPD in the United States

Latest Post

  • BLS International again wins the Contract with the High Commission of India in Canada
  • Vikas Ecotech's Debt Reduction Program
  • REC enters into 200 million Euro Loan Agreement with German Bank KfW
  • TVS Motor Company extends INR 50 Lakhs Relief Aid to Andhra Pradesh
  • Moneyboxx Finance Ltd opens its 83rd branch office


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2022